Adelyx's key Phase 3 trial for the treatment of hyperphosphateemia reaches primary and all secondary endpoints

recently, Ardelyxcompany(http:// announcedthat it had reached its primary and all secondary endpoint scored in the critical phase 3trial(http://for the treatment of hyperphosphateemia in dialysis patientstheDrug(http://Studies have shown that tenapanor is used in combination with phosphate adhesives to significantly reduce phosphate levels in the patient's bloodAbout tenapanor
Ardelyx
's new drug(http://tenapanor is an inhibitor of the gastrointestinal sodium ion transport protein NHE3, which reduces the amount of sodium ions that the gastrointestinal tract ingests from food, thereby increasing the concentration of protons in gastrointestinal cells 　　Tenapanor's inhibition of sodium ion and phosphate absorption is selective and does not affect the intestinal absorption of other ions, molecules and nutrients 　　Tenapanor is a small pill that is easier for patients to take than phosphate adhesives 　　Ardelyx says that once approved, tenapanor could be the basis for treating patients with CKD dialysis with elevated blood phosphorus concentrations 　　A total of 236 CKD patients on hemodialysis were involved in the randomized double-blind Phase 3 trial Although these patients were treated with a stable phosphate adhesive, blood phosphorus concentrations were 5.5 mg/dL and 10.0 mg/dL at screening 　　The results showed that the combination of tenapanor and phosphate adhesives resulted in a significant reduction in blood phosphorus concentration compared to the individual treatment of phosphate adhesives, with patients meeting the blood phosphorus concentration target of 5.5 mg/dL per week 　　In addition, Tenapanor has demonstrated good safety and tolerance